Post-recurrence survival analysis in patients with oligo-recurrence after curative esophagectomy

被引:7
|
作者
Tsai, Ping-Chung [1 ]
Chien, Hung-Che [1 ]
Hsu, Po-Kuei [1 ,2 ]
Hung, Jung-Jyh [1 ,2 ]
Huang, Chien-Sheng [1 ,2 ]
Hsu, Wen-Hu [1 ,2 ]
Hsu, Han-Shui [1 ,2 ]
机构
[1] Taipei Vet Gen Hosp, Div Thorac Surg, Dept Surg, 201,Sec 2,Shih Pai Rd, Taipei, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
关键词
Esophageal cancer; Oligo-recurrence; Post-recurrence survival; LYMPH-NODE RECURRENCE; SQUAMOUS-CELL CARCINOMA; OLIGOMETASTASES; CANCER; CHEMORADIOTHERAPY; OUTCOMES; METASTASECTOMY;
D O I
10.1186/s12885-022-09739-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Recurrent esophageal cancer is associated with dismal prognosis. There is no consensus about the role of surgical treatments in patients with limited recurrences. This study aimed to evaluate the role of surgical resection in patients with resectable recurrences after curative esophagectomy and to identify their prognostic factors. Methods We retrospectively reviewed patients with recurrent esophageal cancer after curative esophagectomy between 2004 and 2017 and included those with oligo-recurrence that was amenable for surgical intent. The prognostic factors of overall survival (OS) and post-recurrence survival (PRS), as well as the survival impact of surgical resection, were analyzed. Results Among 654 patients after curative esophagectomies reviewed, 284 (43.4%) had disease recurrences. The recurrences were found resectable in 63 (9.6%) patients, and 30 (4.6%) patients received surgery. The significant prognostic factors of PRS with poor outcome included mediastinum lymph node (LN) recurrence and pathologic T3 stage. In patients with and without surgical resection for recurrence cancer, the 3-year OS rates were 65.6 and 47.6% (p = 0.108), while the 3-year PRS rates were 42.9 and 23.5% (p = 0.100). In the subgroup analysis, surgery for resectable recurrence, compared with non-surgery, could achieve better PRS for patients without any comorbidities (hazard ratio 0.36, 95% CI: 0.14 to 0.94, p = 0.038). Conclusions Mediastinum LN recurrence or pathologic T3 was associated with worse OS and PRS in patients with oligo-recurrences after curative esophagectomies. No definite survival benefit was noted in patients undergoing surgery for resectable recurrence, except in those without comorbidities.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: A Bi-institutional validated risk classification
    van Oosten, A. Floortje
    Daamen, Lois A.
    Groot, Vincent P.
    Biesma, Nanske C.
    Habib, Joseph R.
    van Goor, Iris W. J. M.
    Kinny-Koster, Benedict
    Burkhart, Richard A.
    Wolfgang, Christopher L.
    van Santvoort, Hjalmar C.
    He, Jin
    Molenaar, Quintus
    EJSO, 2023, 49 (09):
  • [32] Oligo-progressive status exhibits unfavorable survival in pulmonary oligo-recurrence treated by SABR
    Lee, H.
    Tsai, J.
    Chen, S.
    Lai, I.
    Chen, C.
    Ho, C.
    Chiou, J.
    Kuo, Y.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S741 - S742
  • [33] Oligo-recurrence and Sync-oligometastases In Response
    Niibe, Yuzuru
    Jingu, Keiichi
    Onishi, Hiroshi
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : E59 - E60
  • [34] Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: A single-center experience
    Zhang, Wei
    Zhao, Gang
    Wei, Kai
    Zhang, Qingxiang
    Ma, Weiwei
    Song, Tianqiang
    Wu, Qiang
    Zhang, Ti
    Kong, Dalu
    Li, Qiang
    BIOSCIENCE TRENDS, 2014, 8 (06) : 333 - 338
  • [35] Additional chemotherapy improved local control and overall survival after stereotactic body radiation therapy for patients with oligo-recurrence
    Masaki Nakamura
    Naoki Hashimoto
    Hiroshi Mayahara
    Haruka Uezono
    Aya Harada
    Ryo Nishikawa
    Yoshiro Matsuo
    Hiroki Kawaguchi
    Hideki Nishimura
    Radiation Oncology, 13
  • [36] Recurrence patterns and post-recurrence survival of patients with bilobar colorectal liver metastases: international multicentre retrospective study
    Siriwardena, Ajith K.
    Serrablo, Alejandro
    Novotny, Alexander
    Know, Alfred
    Kourdouli, Amar
    Belli, Andrea
    Laurenzi, Andrea
    Valdivieso, Andres
    Hann, Angus
    de la Hoz Rodriguez, Angela
    Oona, Anisa Nutu
    Pascher, Andreas
    Frena, Antonio
    Varona-Bosque, Aranzazu
    Ivanecz, Arpad
    Heumann, Asmus
    Alonso Alvarado, Ayaya
    Kaldarov, Ayrat
    Bracke, Bart
    Hendrikx, Bart
    Struecker, Benjamin
    Bjornsson, Bergthor
    Dasari, Bobby V. M.
    Cutolo, Carmen
    Frola, Carlo
    Paya-Llorente, Carmen
    Domingo-del Pozo, Carlos
    Teh, Catherine
    Stoess, Christian
    Sturesson, Christian
    Ricci, Claudio
    Verhoef, Cornelis
    Dopazo, Cristina
    Galun, Daniel
    Hartmann, Daniel
    Martin, David
    Vaz da Silva, Diego Greatti
    Dorcaratto, Dimitri
    Raptis, Dimitri
    Magouliotis, Dimitrios
    Moris, Dimitrios
    Symeonidis, Dimitrios
    Zacharoulis, Dimitrios
    Bugra, Dursun
    Lopez-Garnica, Dolores
    Jonas, Eduard
    Muttillo, Edoardo Maria
    Saladino, Edoardo
    Francisco, Elsa
    Hutten, Ela
    BJS-BRITISH JOURNAL OF SURGERY, 2025, 112 (03):
  • [37] Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases
    Angelsen, Jon-Helge
    Viste, Asgaut
    Loes, Inger Marie
    Eide, Geir Egil
    Hoem, Dag
    Sorbye, Halfdan
    Horn, Arild
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2015, 13
  • [38] Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases
    Jon-Helge Angelsen
    Asgaut Viste
    Inger Marie Løes
    Geir Egil Eide
    Dag Hoem
    Halfdan Sorbye
    Arild Horn
    World Journal of Surgical Oncology, 13
  • [39] Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes
    Kuikui Jiang
    Danyang Zhou
    Fei Xu
    Wen Xia
    Qiufan Zheng
    Qianyi Lu
    Rongzhen Luo
    Ruoxi Hong
    Shusen Wang
    BMC Cancer, 23 (1)
  • [40] ROLE OF STEREOTACTIC RADIOTHERAPY IN OLIGO-RECURRENCE OF PLEURAL MESOTHELIOMA
    Revelant, Alberto
    Gessoni, Francesca
    Barresi, Loredana
    Drigo, Annalisa
    Pirrone, Giovanni
    Polesel, Jerry
    Vinante, Lorenzo
    Caroli, Angela
    Bertini, Federica
    Gorza, Anna
    Fanetti, Giuseppe
    Navarria, Federico
    Palazzari, Elisa
    Matrone, Fabio
    Donofrio, Alessandra
    Mascarin, Maurizio
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1768 - S1771